633 The Relative Abundances of Dorea and Faecalibacterium spp. in the Mucosa Associated Microbiome of Newly Diagnosed Children With Crohn's Disease Are Differentially Affected by Exclusive Enteral Nutrition

2016 ◽  
Vol 150 (4) ◽  
pp. S132-S133 ◽  
Author(s):  
Zubin Grover ◽  
Alicia Kang ◽  
Mark Morrison ◽  
Graham L. Radford-Smith ◽  
Naoki Fukuma ◽  
...  
2013 ◽  
Vol 58 (12) ◽  
pp. 3584-3591 ◽  
Author(s):  
Jason Soo ◽  
Bushra A. Malik ◽  
Justine M. Turner ◽  
Rabin Persad ◽  
Eytan Wine ◽  
...  

2014 ◽  
Vol 8 ◽  
pp. S395-S396
Author(s):  
N.O. Kaakoush ◽  
A.S. Day ◽  
S.T. Leach ◽  
D.A. Lemberg ◽  
S. Nielsen ◽  
...  

2013 ◽  
Vol 63 (1-2) ◽  
pp. 10-16 ◽  
Author(s):  
Katharina Julia Werkstetter ◽  
Stephanie Barbara Schatz ◽  
Martin Alberer ◽  
Birgit Filipiak-Pittroff ◽  
Sibylle Koletzko

Nutrients ◽  
2020 ◽  
Vol 12 (4) ◽  
pp. 1012
Author(s):  
Melinda Moriczi ◽  
Gemma Pujol-Muncunill ◽  
Rafael Martín-Masot ◽  
Santiago Jiménez Treviño ◽  
Oscar Segarra Cantón ◽  
...  

Exclusive enteral nutrition (EEN) has been shown to be more effective than corticosteroids in achieving mucosal healing in children with Crohn´s disease (CD) without the adverse effects of these drugs. The aims of this study were to determine the efficacy of EEN in terms of inducing clinical remission in children newly diagnosed with CD, to describe the predictive factors of response to EEN and the need for treatment with biological agents during the first 12 months of the disease. We conducted an observational retrospective multicentre study that included paediatric patients newly diagnosed with CD between 2014–2016 who underwent EEN. Two hundred and twenty-two patients (140 males) from 35 paediatric centres were included, with a mean age at diagnosis of 11.6 ± 2.5 years. The median EEN duration was 8 weeks (IQR 6.6–8.5), and 184 of the patients (83%) achieved clinical remission (weighted paediatric Crohn’s Disease activity index [wPCDAI] < 12.5). Faecal calprotectin (FC) levels (μg/g) decreased significantly after EEN (830 [IQR 500–1800] to 256 [IQR 120–585] p < 0.0001). Patients with wPCDAI ≤ 57.5, FC < 500 μg/g, CRP >15 mg/L and ileal involvement tended to respond better to EEN. EEN administered for 6–8 weeks is effective for inducing clinical remission. Due to the high response rate in our series, EEN should be used as the first-line therapy in luminal paediatric Crohn’s disease regardless of the location of disease and disease activity.


2021 ◽  
Vol 94 (4) ◽  
pp. 252-253
Author(s):  
Alicia Isabel Pascual Pérez ◽  
Gemma Pujol Muncunill ◽  
Patricia Domínguez Sánchez ◽  
Sara Feo Ortega ◽  
Javier Martín de Carpi

Sign in / Sign up

Export Citation Format

Share Document